Hōʻike hou ka ʻikepili hou mai ka haʻawina ʻo Phase 3 i ka pono o VUMERITY® (Dilosimil fumarate) a hoʻomaikaʻi i ka hoʻomanawanui ʻana o ka ʻōpū.
Hoʻohālikelike ʻia me Ocrevus® (ocrelizumab), ua loiloi nā ʻike maoli i ka maikaʻi o nā pono ola e pili ana me TYSABRI® (natalizumab)
Hōʻike nā mea ʻē aʻe i ke ola maoli i nā pono maikaʻi o PLEGRIDY® (peginterferon beta-1a) a me AVONEX® (interferon beta-1a) i nā poʻe maʻi maʻi me ka sclerosis lehulehu.
Cambridge, Massachusetts, Kepakemapa 11, 2020 (Global News)-Biogen Inc. (NASDAQ: BIIB) i kēia lā hoʻolaha i ka ʻikepili hou e hōʻike ana i kāna ʻoihana-alakaʻi lehulehu sclerosis (MS) Efficacy a me ka palekana o ka hui therapeutic.E hōʻike ʻia kēia mau ʻikepili i ka hui hui ʻewalu o MSVirtual2020, ka American Multiple Sclerosis Treatment and Research Committee a me ka European Multiple Sclerosis Treatment and Research Committee (ACTRIMS-ECTRIMS), e mālama ʻia mai Kepakemapa 11 a 13, 2020.
Ua ʻōlelo ʻo Biogen Chief Medical Officer Maha Radhakrishnan, MD: "Haʻaheo ʻo Biogen no ka mea ua kūpaʻa mākou i ka hoʻoponopono ʻana i nā pilikia koʻikoʻi a lōʻihi e kū nei i nā maʻi MS."ʻO ka ʻikepili a mākou e hāʻawi ai ma ACTRIMS-ECTRIMS e hōʻike ana i nā hopena i hoʻomaikaʻi ʻia.Ke hoʻomau nei kā mākou waihona huahana MS nui e lawelawe i nā poʻe maʻi me ka MS relapsing, ʻaʻohe mea i kahi o lākou i ke kaʻina hana lapaʻau, a me kā mākou mau noiʻi a me ka hoʻomohala ʻana i ka hoʻomohala ʻana i nā moho lāʻau lapaʻau kūpono.”
Hōʻike hou ka ʻikepili hou o ka Phase 3 i ka pono o VUMERITY® (Dilosimide fumarate) a me ka hoʻomanawanui GI i hōʻike ʻia e ka mea maʻi.Hōʻike hou ka ʻikepili hou mai ka papahana lapaʻau VUMERITY Phase 3 i ka hopena o ka lāʻau fumarate waha hou loa o Biogen.Ke hoʻohālikelike ʻia me TECFIDERA® (dimethyl fumarate) (n = 251) a me ke kākoʻo, ua hoʻoikaika nā hopena o ka noiʻi ʻo EVOLVE-MS-2 ʻelima mau pule i ka hoʻomanawanui ʻana o ka ʻōpū (GI) o nā maʻi i loiloi ʻia e pili ana i ka mālama ʻana i ka VUMERITY ʻO ke koʻikoʻi o ka hoʻomaʻamaʻa ʻana (n). = 253) hoʻomaikaʻi i kona hopena i ka maikaʻi o ke ola o nā maʻi me MS mau.Ua ʻōlelo ka poʻe i komo i ke aʻo ʻana e lawe ana i ka VUMERITY he liʻiliʻi paha lākou e hoʻomohala i nā hōʻailona ʻōpū e hoʻopilikia i nā hana o kēlā me kēia lā a i ʻole pili i ka nele o ka hana, a ʻoi aku ka liʻiliʻi o nā lāʻau i hoʻohana ʻia e mālama i nā hōʻailona ʻōpū.
Ua loiloi ka ʻimi noiʻi ʻana o ka noiʻi ʻo EVOLVE-MS-1 i ka hopena o VUMERITY i ka loli o ka lolo a me nā hōʻailona lapaʻau ʻē aʻe i ka poʻe me MS relapsed (n = 365) i mālama ʻia a hiki i ʻelua makahiki.Ua hōʻike ʻia nā haʻawina ʻokoʻa e pili ana ka emi ʻana o ka nui o ka lolo me ka hōʻino ʻana i ka naʻau, ke kīnā kino a me ka emi ʻana o ke ola o nā maʻi MS.1,2, hōʻike ka ʻikepili o EVOLVE-MS-1:
Ua like ka nui o ka loli o ka lolo o ka poʻe i loaʻa i ka VUMERITY no ʻelua makahiki me ka poʻe olakino olakino.me
Ma kahi o 90% o nā poʻe maʻi e loaʻa ana i ka VUMERITY ʻaʻole i hōʻoia i ka holomua o ke kīnā, a ma kahi o 84% ʻaʻole i loaʻa hou i loko o ʻelua makahiki.
E hōʻike ʻia ka ʻikepili hope loa mai ka haʻawina Phase 3 o ENDORSE ma ka ʻaha kūkā, kahi e hōʻike hou ai i ka pono mau a me ka palekana i wehewehe maikaʻi ʻia o TECFIDERA i nā maʻi a hiki i 13 makahiki.
Hōʻike ka ʻikepili maoli mai kahi hoʻokaʻawale ʻokoʻa o ka heluna MS hou ma o MS PATHS (Partner Advance Technology and Health Solutions), TYSABRI® (natalizumab), PLEGRIDY® (pegylated interferon beta-1a) A me AVONEX® (interferon beta-1a) nā hopena. ua holomua., Ke hana pū nei ʻo Biogen me nā kikowaena MS alakaʻi ma ʻEulopa a me ʻAmelika Hui Pū ʻIa e hoʻopuka i ka ʻikepili maʻamau, kiʻekiʻe kiʻekiʻe mai nā heluna kanaka maʻi MS maoli.I kēia lā, ʻoi aku ma mua o 17,000 mau mea maʻi i komo i MS PATHS.ʻO ka ʻikepili i loaʻa mai ka mālama ʻana i ke kaiapuni maoli e kākoʻo i nā hopena i hoʻomaikaʻi ʻia e pili ana me TYSABRI, PLEGIDYY a me AVONEX.Hōʻike nā hopena o kahi hoʻokaʻawale ʻokoʻa mai ka ʻikepili MS PATHS:
Ma ka hoʻohālikelike mua o ka MS PATHS standard magnetic resonance imaging (MRI) regimen, ua hoʻohālikelike ʻia nā hoʻololi i ka wā lōʻihi o ka manawa dosing (EID; n = 85) o natalizumab i ka MRI lolo i ʻae ʻia (mean follow-up 0.8 makahiki).I kēlā me kēia pule ʻehā (Q4W; n = 569).ʻAʻole i hōʻike ʻia nā ʻokoʻa koʻikoʻi o ka maʻi T2 hou, nā ʻano maʻi T2 a me ka helu atrophy o ka lolo.ʻO nā ʻokoʻa o nā mea ʻimi MRI a me nā protocols loaʻa i ka hana lapaʻau e hoʻohālikelike i nā hopena MRI lolo.Ua hōʻike ʻia nā haʻawina he nui o ka honua maoli i ka maikaʻi o ka natalizumab EID e like me ka helu Q4W i ʻāpono ʻia.Ke hoʻomau nei ʻo 3-7Biogen i ka loiloi i ka pono, palekana a me ka ʻae ʻana o natalizumab EID ma o ka hoʻāʻo ʻana o NOVA (NCT03689972), a ua hoʻouna koke ʻo ia i kahi noi no ka hoʻokele subcutaneous i ka mana hoʻoponopono.Inā ʻae ʻia, E hāʻawi ia i nā koho hou aʻe no ka hoʻokele TYSABRI.
Wahi a Neuro-QoL (Quality of Life in Nervous System Diseases), ʻoi aku ka maikaʻi o ka mālama ʻana iā TYSABRI i kekahi ʻano o ke ola ma mua o Ocrevus® (ocrelizumab).I loko o kahi loiloi subgroup o nā mea maʻi i hoʻohālikelike ʻia me TYSABRI a i ʻole Ocrevus, ua ʻike ʻia ʻo 9 o 12 mau kikowaena Neuro-QoL i nā mea maʻi i mālama ʻia me TYSABRI ua hoʻomaikaʻi maikaʻi ʻia (n = 144).Ua hoʻomaikaʻi maikaʻi ʻia ʻo 4 o 12 mau kikowaena (n = 502)).ʻO ka holoʻokoʻa, ʻoi aku ka kiʻekiʻe o ka hoʻomaikaʻi makahiki o TYSABRI ma mua o Ocrevus, a ʻike ʻia nā ʻokoʻa koʻikoʻi ma nā ʻano ʻekolu: ka hopena maikaʻi a me ka maikaʻi, ka ʻoluʻolu i nā kuleana a me nā hana, a me nā maʻi hiamoe.
Ke hoʻohālikelike ʻia me nā maʻi MS ma lalo o 60 mau makahiki (n = 729), ua hōʻike nā hopena lapaʻau o nā maʻi MS ma luna o 60 mau makahiki (n = 286) i nā hui makahiki ʻelua, hiki i ka PLEGRIDY a me AVONEX ke hāʻawi i nā pono hana.Hōʻike ka ʻikepili i ka hoʻomaʻamaʻa wikiwiki ʻana (PST) a me ka hoʻāʻo ʻokoʻa ʻokoʻa (CST) o nā pūʻulu makahiki ʻelua i ʻoi aku ka maikaʻi ma mua o hoʻokahi makahiki.Eia kekahi, ʻaʻole i hoʻi hou ka hapa nui o ka poʻe i komo i loko o ʻelua mau makahiki.
Kākoʻo ka ʻikepili mai ka haʻawina Phase 1 o BIIB091 i ka mālama mau ʻana o MSBiogen, a hāʻawi pū ʻia nā ʻikepili mai ka haʻawina Phase 1 o BIIB091.ʻO BIIB091 kahi mea hoʻopaneʻe mole liʻiliʻi a hiki ke hoʻohuli i ka hana waha a Bruton's tyrosine kinase (BTK) Agen.Ua loiloi ka ʻikepili i ka palekana, ka hoʻomanawanui, ka pharmacokinetics a me ka pharmacodynamics o ka hoʻokahi a me ka piʻi nui ʻana o ka waha waha i nā kumuhana olakino olakino.Hiki ke hoʻopōmaikaʻi ʻia ka pale BTK koho i ka mālama ʻana iā MS ma ka pale ʻana i ka hoʻōla ʻana o nā pūnaewele B a me nā cell myeloid me ka ʻole o ka pau ʻana o nā cell immune.
Hōʻike ʻikepili ma ACTRIMS-ECTRIMS: Nānā: E loaʻa nā hōʻikeʻike pepa āpau o MSVirtual2020 ma ka pūnaewele ma 8 AM Eastern Time ma ka Pōʻalima, Kepakemapa 11, 2020.
Hoʻohālikelike ʻia me ka dimethyl fumarate ma EVOLVE-MS-2, ʻoi aku ka maikaʻi o ka hoʻomanawanui ʻana o GI o Diroximel fumarate e pili nui ana i ke koʻikoʻi o ka maikaʻi o ke ola (Poster 0214)
ʻO ka hopena o Diroximel fumarate i ka loli o ka lolo a me ka piʻi ʻana o ke kīnā i nā pākeke me EVOLVE-MS-1 relapsing-remitting multiple sclerosis (Poster P0205)
ʻO ka palekana a me ka maikaʻi o nā maʻi i mālama ʻia me ka dimethyl fumarate a hahai ʻia no 13 mau makahiki: nā hopena hope loa o ENDORSE (platform FC02.05-Sunday, September 13th 1:48-2:00 US Eastern Time)
ʻAʻole ʻokoʻa nā hopena radiology o nā poʻe maʻi me nā kauā wā lōʻihi o Natalizumab mai nā ʻāpana wā maʻamau ma MS PATHS (Poster P0360)
Ka hopena o Natalizumab i ka maikaʻi o ke ola ma kahi hui maoli o nā maʻi sclerosis lehulehu: nā hopena o ke ala MS (Poster P1036)
Nā hiʻohiʻona a me nā hopena lapaʻau o nā poʻe maʻi MS kahiko me Peginterferon Beta-1a a i ʻole intramuscular interferon Beta-1a i ka mālama ʻana i ke ala MS (Poster P0843)
Hoʻopaʻa haʻawina ʻo ka pae 1 o BIIB091 (he mea hoʻopaneʻe ʻo Bruton's tyrosine kinase (BTK) i nā poʻe mākua olakino: nā hopena mua (poster P0186)
E pili ana i ka VUMERITY® (Dilosemate Fumarate) ʻO VUMERITY he fumarate waha me kahi ʻano kemika ʻokoʻa loa mai TECFIDERA® (Dimethyl Fumarate), i ʻae ʻia ma ʻAmelika no ka mālama ʻana i nā maʻi sclerosis lehulehu i nā pākeke ʻO nā ʻano maʻi mau o ka maʻi e pili ana i nā syndromes isolated clinically. nā maʻi hou a me nā maʻi holomua lua.Ma hope o ke komo ʻana i ke kino, hoʻololi koke ʻia ʻo VUMERITY i monomethyl fumarate, ka metabolite ikaika like o ka dimethyl fumarate.
Hoʻopaʻa ʻia ʻo VUMERITY i nā poʻe maʻi i maʻi i ka Diroximel fumarate, dimethyl fumarate a i ʻole kekahi o nā mea kōkua o VUMERITY;a me nā poʻe maʻi e lawe ana i ka dimethyl fumarate.Hoʻokumu ʻia nā hopena koʻikoʻi o VUMERITY ma ka ʻikepili o dimethyl fumarate (ʻo ia ka metabolite ikaika e like me VUMERITY), me nā hopena maʻi a me ka angioedema, progressive multifocal leukoencephalopathy, ʻo ia ka lolo opportunistic loaʻa ka maʻi Viral pili i ka make a i ʻole ka maʻi koʻikoʻi.ʻO ke kīnā ʻole, hoʻemi ʻia ka helu lymphocyte awelika i ka makahiki mua o ka mālama ʻana, nā maʻi maʻi maʻi a me nā maʻi koʻikoʻi ʻē aʻe, ka pōʻino o ke ake a me ka ʻili ʻana.ʻO nā hanana ʻino maʻamau i loaʻa me ka hoʻohana ʻana i ka ʻikepili mai ka dimethyl fumarate (me ka metabolite ikaika like me VUMERITY) ʻo ka ʻili ʻana, ka ʻeha ʻōpū, ka ʻōpū, a me ka nausea.
E ʻoluʻolu e kaomi ma aneʻi no ka ʻike palekana koʻikoʻi a me ka ʻike kikoʻī piha, me ka ʻike maʻi no VUMERITY ma United States.
E pili ana i TECFIDERA® (dimethyl fumarate) ʻO TECFIDERA kahi ala lapaʻau no ka hoʻihoʻi ʻana i ka maʻi sclerosis (MS) i nā pākeke.ʻO ia ka lāʻau lapaʻau i kuhikuhi ʻia no ka hoʻihoʻi ʻana o MS ma ka honua.Ua hōʻoia ʻia e hōʻemi i ka hoʻihoʻi hou ʻana o MS a lohi i lalo.Ke holomua nei i ke kino kīnā a pili i ka heluna o nā ʻeha lolo MS, a hōʻoia i ka maikaʻi o ke ʻano palekana o nā maʻi me MS relapsed.Ua ʻae ʻia ʻo TECFIDERA ma 69 mau ʻāina / ʻāpana a ua mālama ʻia no nā maʻi 475,000, ʻo ia hoʻi ma mua o 950,000 mau makahiki hoʻomanawanui o nā maʻi e hoʻohana ana a kuhikuhi iā TECFIDERA.ʻO kēia, 6,335 mau maʻi (14,241 mau makahiki maʻi) i hele mai mai nā hoʻokolohua lapaʻau8.
Hoʻopaʻa ʻia ʻo TECFIDERA i nā poʻe maʻi i maʻi i ka dimethyl fumarate a i ʻole kekahi o nā mea kōkua o TECFIDERA.ʻO nā hopena koʻikoʻi e pili ana i nā hopena maʻi a me ka angioedema, a me nā hihia o ka leukoencephalopathy multifocal holomua (nā maʻi viral opportunistic lolo e pili ana me ka make a i ʻole ke kīnā koʻikoʻi) ua ʻike ʻia i nā maʻi TECFIDERA me ka lymphopenia lōʻihi, ʻoiai ʻaʻole maopopo ke kuleana o lymphopenia i kēia mau hihia. .ʻO nā hopena koʻikoʻi ʻē aʻe e pili ana i ka emi ʻana o ka helu lymphocyte awelika i ka makahiki mua o ka mālama ʻana, nā shingles a me nā maʻi koʻikoʻi ʻē aʻe, ka pōʻino o ka ate a me ka ʻili.I loko o nā hoʻokolohua lapaʻau, ʻo nā hanana ʻino loa e pili ana me TECFIDERA ʻo ka ʻili ʻana, ka ʻeha o ka ʻōpū, ka ʻōpū a me ka nausea.
E ʻoluʻolu e kaomi ma aneʻi no ka ʻike palekana koʻikoʻi a me ka ʻike kikoʻī piha, me ka ʻike maʻi no TECFIDERA ma ʻAmelika Hui Pū ʻIa, a i ʻole e kipa i ka pūnaewele huahana ma kou ʻāina/'āpana.
E pili ana iā TYSABRI® (natalizumab) He lāʻau lapaʻau maikaʻi ʻo TYSABRI no ka hoʻihoʻi ʻana i ka sclerosis lehulehu (RMS), hiki ke hoʻohana ʻia no ka hoʻihoʻi ʻana i ka MS i nā pākeke.Ua hōʻoia nā hoʻokolohua lapaʻau e hiki i kēia lapaʻau ke hoʻolōʻihi i ka piʻi ʻana o ke kino kīnā a hoʻemi i ka hoʻokumu ʻana o nā ʻeha lolo hou a hoʻemi i ka hoʻi hou ʻana.Ua ʻae ʻia ʻo TYSABRI ma 80 mau ʻāina / ʻāpana.Wahi a nā hoʻokolohua lapaʻau a me ka ʻikepili kuhikuhi, ua loaʻa iā TYSABRI ka mālama ʻana iā TYSABRI no ka ʻoi aku o 213,000 poʻe ma ka honua holoʻokoʻa, me ka ʻoi aku o 835,000 mau makahiki maʻi o ka ʻike.9
Hoʻonui ʻo TYSABRI i ka hopena o ka progressive multifocal leukoencephalopathy (PML), kahi maʻi viral opportunistic o ka lolo i pili i ka make a i ʻole ke kīnā koʻikoʻi.ʻO ke kumu pilikia e hoʻonui ai i ka pilikia o ka PML ʻo ia ka hele ʻana o nā antibodies anti-JC virus, ka hoʻohana ʻana i nā mea immunosuppressive a me TYSABRI no ka mālama lōʻihi.ʻO ka poʻe maʻi me kēia mau mea pilikia ʻekolu ka nui o ka pilikia o ka PML.Ke hoʻomaka a hoʻomau i ka mālama ʻana me TYSABRI, pono e noʻonoʻo nā kauka inā lawa nā pono i manaʻo ʻia o TYSABRI e hoʻopau i kēia pilikia.
Hoʻonui pū ʻo TYSABRI i ka hoʻomohala ʻana i ka encephalitis a me ka maningitis i hoʻokumu ʻia e nā maʻi herpes simplex a me varicella-zoster.Wahi a nā hōʻike, ʻo nā mea maʻi MS e loaʻa ana iā TYSABRI he mau hihia koʻikoʻi, hoʻoweliweli i ke ola a hiki i ka make ma hope o ka mākeke.I loko o ke kaiapuni ma hope o ka kūʻai ʻana, aia pū kekahi i ka pōʻino o ke akepaʻa koʻikoʻi, me ka hāʻule ʻole o ka ate e pono ai ke hoʻololi.ʻO nā hanana koʻikoʻi ʻē aʻe i loaʻa i nā poʻe maʻi i mālama ʻia me TYSABRI, ʻo ia ka hopena hypersensitivity (e like me ka hopena allergy) a me nā maʻi, me nā maʻi opportunistic a me nā maʻi atypical ʻē aʻe.
E ʻoluʻolu e kaomi ma aneʻi no ka ʻike palekana koʻikoʻi, me nā ʻōlelo aʻo pahu pahu, a me ka ʻike kikoʻī piha, me ke alakaʻi lāʻau lapaʻau US TYSABRI, a i ʻole e kipa i ka pūnaewele huahana ma kou ʻāina/'āpana.
E pili ana i ka PLEGRIDY® (pegylated interferon β-1a) ʻO PLEGRIDY kahi interferon pegylated subcutaneous, hoʻokahi manawa i kēlā me kēia pule ʻelua, no ke ʻano hou o ka multiple sclerosis (MS) i nā pākeke, ʻo ia ke ʻano maʻamau o MS.ʻAno maʻamau.Ua ʻae ʻia ʻo PLEGRIDY i kēia manawa ma mua o 60 mau ʻāina / ʻāpana, me ʻAmelika Hui Pū ʻIa, Kanada, Australia a me Switzerland, a me ka Hui ʻEulopa holoʻokoʻa.Wahi a ka ʻikepili kuhikuhi, kokoke i ka 57,000 poʻe ma ka honua holoʻokoʻa i loaʻa i ka mālama PLEGRIDY, me ka ʻoi aku o 107,000 mau makahiki maʻi o ka ʻike.Ke hoʻomau nei ʻo 10Biogen i ka hana e hoʻolako i ka PLEGRIDY ma nā ʻāina a puni ka honua.
Kākoʻo ʻia ka maikaʻi a me ka palekana o PLEGRIDY e kekahi o nā haʻawina pivotal nui loa, nāna i hoʻohana i ka interferon therapy i nā maʻi me ka relapsing-remitting MS.Ma nā haʻawina hoʻokolohua, ua hōʻike ʻia e hiki i ka PLEGRIDY ke hoʻemi nui i ka helu hoʻi hou o MS, e hoʻolohi i ka piʻi ʻana o ke kīnā a hoʻemi i ka nui o nā ʻeha lolo ma MS.I ka manawa like, ua hōʻike ʻia he maikaʻi ka palekana o nā mea maʻi me MS relapsed.ʻO nā hopena ʻaoʻao i hōʻike ʻia e pili ana i nā pilikia o ka ate, me ka hāʻule ʻole o ka ate a me ka hoʻonui ʻana i nā enzyme o ka ate;ke kaumaha a i ʻole nā ​​manaʻo suicidal;nā hopena maʻi nui;nā pilikia o ka naʻau, e like me ka puʻuwai congestive;nā maʻi autoimmune;hoʻemi ʻia ka helu o ke koko keʻokeʻo a i ʻole platelet;a me ka hopu.I loko o nā hoʻokolohua lapaʻau, ʻo nā hopena ʻino loa e pili ana me PLEGRIDY ʻo ia ka hopena o ka wahi injection a me nā hōʻailona like-flu.Hiki ke loaʻa kahi papa inoa o nā hanana ʻino ma ka lepili huahana PLEGRIDY piha no kēlā me kēia ʻāina i ʻike ʻia.
E ʻoluʻolu e kaomi ma aneʻi no ka ʻike palekana koʻikoʻi a me ka ʻike kikoʻī kikoʻī, me nā alakaʻi lapaʻau US PLEGRIDY, a i ʻole e kipa i ka pūnaewele huahana ma kou ʻāina/'āpana.
No AVONEX® (Interferon beta-1a) Ua koho ʻia ʻo AVONEX no ka hoʻihoʻi ʻana i ka MS, a ua ʻae ʻia ma nā ʻāina ʻoi aku ma mua o 90.Wahi a ka ʻikepili kuhikuhi, ʻoi aku ma mua o 580,000 poʻe ma ka honua holoʻokoʻa i loaʻa i ka lāʻau AVONEX, me ka ʻoi aku o 2.6 miliona mau makahiki maʻi o ka ʻike.Ua koho ʻia ʻo 11AVONEX no ka mālama ʻana i ka relapsing multiple sclerosis (MS), me nā syndromes isolated clinically, relapsing-pakeke me ka maʻi ʻeha a me ka maʻi holomua lua.
Wahi a nā hōʻike, loaʻa i nā maʻi e loaʻa ana iā AVONEX nā hōʻailona o ke kaumaha, manaʻo suicidal a i ʻole psychosis, a ua piʻi ka pinepine o nā hihia pepehi kanaka.He liʻiliʻi nā poʻe maʻi e hōʻike ana i ka pōʻino nui o ka ate, me ka hāʻule ʻole o ka ate.Ua hōʻike ʻia nā hihia kakaʻikahi o ka maʻi maʻi.ʻOiai ʻaʻole loaʻa ka beta interferon i kahi ʻawaʻawa puʻuwai pololei, ua hōʻike ʻia ʻaʻohe mea maʻi i ʻike ʻia i hoʻomohala ʻia ka puʻuwai congestive, cardiomyopathy, a me ka cardiomyopathy o ka pau ʻole o ka naʻau congestive.Hōʻike ka ʻike ma hope o ke kūʻai ʻana ua hoʻemi ʻia ka helu o ke koko peripheral.Wahi a nā hōʻike, loaʻa i nā poʻe maʻi e hoʻohana ana i ka AVONEX i ka hopu ʻana, me ka poʻe me ka ʻole o ka moʻolelo o ka hopu.Ua hōʻike ʻia nā maʻi autoimmune o nā ʻāpana he nui.Manaʻo ʻia e hana maʻamau i ka kemika koko, ka hematology, ka hana ate a me nā hoʻāʻo hana thyroid i kēlā me kēia manawa.
E ʻoluʻolu e kaomi ma aneʻi no ka ʻike palekana koʻikoʻi a me ka ʻike kikoʻī piha, me nā alakaʻi lapaʻau lāʻau no AVONEX ma United States, a i ʻole e kipa i ka pūnaewele huahana ma kou ʻāina/'āpana.
E pili ana i Biogen Ma Biogen, maopopo kā mākou misionari: he mau paionia mākou ma ke kahua o ka neuroscience.ʻIke, hoʻomohala a hāʻawi ʻo Biogen i nā lāʻau lapaʻau hou i ka honua no ka poʻe i loaʻa i nā maʻi neurological koʻikoʻi a me nā maʻi neurodegenerative a me nā lāʻau lapaʻau pili.ʻO Biogen kekahi o nā hui biotechnology mua loa o ka honua, i hoʻokumu ʻia i ka makahiki 1978 e Charles Weissmann, Heinz Schaller, Kenneth Murray, a me nā mea lanakila no ka Nobel Prize Walter Gilbert lāua ʻo Phillip Sharp.I kēia lā, loaʻa ʻo Biogen i kahi waihona lāʻau lapaʻau alakaʻi no ka mālama ʻana i ka maʻi sclerosis lehulehu, ua hoʻokuʻu i ka lāʻau atrophy muscle spinal mua i ʻae ʻia, nā biosimilars kūʻai o nā mea ola holomua, a ua kālele ʻia i ka holomua ʻana i ka sclerosis lehulehu a me ka neuroimmunology.ʻO ka maʻi o Alzheimer a me ka dementia, nā maʻi neuromuscular, nā maʻi neʻe, ophthalmology, immunology, neurocognitive disorders, acute neuropathy a me ka ʻeha.
E hoʻolaha mau mākou i ka ʻike i mea nui i nā mea hoʻopukapuka ma kā mākou pūnaewele www.biogen.com.No ka ʻike hou aku, e ʻoluʻolu e kipa www.biogen.com a e hahai mai iā mākou ma ka pāpili kaiapili Twitter, LinkedIn, Facebook, YouTube.
ʻO Biogen Safe Harbor Aia kēia hoʻolaha paʻi i nā ʻōlelo e nānā ana i mua, me nā ʻōlelo e pili ana i nā pono kūpono, palekana a me ka pono o VUMERITY, TECFIDERA, TYSABRI, PLEGIDY a me BIIB091 ma lalo o nā ʻōlelo palekana o ke Private Securities Litigation Reform Act o 1995;Nā hopena o kekahi ʻikepili maoli;EVOLVE-MS-2 haʻawina, ENDORSE Phase 3 aʻo a me BIIB091 Phase 1 nā hualoaʻa;ʻIke a me ka mālama ʻana o MS;kā mākou papahana hoʻolālā hoʻolālā MS;Kūkākūkā hoʻoponopono kūpono, hoʻouna a ʻae ʻia a me nā hoʻonohonoho manawa;ka hiki o ka ʻoihana kalepa a Biogen, me VUMERITY, TECFIDERA, TYSABRI, PLEGRIDY a me BIIB091;a me nā pilikia a me ka maopopo ʻole e pili ana i ka hoʻomohala ʻana i ka lāʻau lapaʻau a me ke kālepa ʻana.Hiki i kēia mau ʻōlelo i mua ke hoʻohana i nā huaʻōlelo e like me "target", "manaʻo", "manaʻo", "hiki" hoʻomaopopo."," "hoʻolālā", "hiki", "hiki", "will", "will" a me nā huaʻōlelo a me nā huaʻōlelo like ʻole.ʻO ka hoʻomohala ʻana i nā lāʻau lapaʻau a me ka hoʻolaha ʻana e pili ana i kahi kūlana kiʻekiʻe o ka pilikia, a he helu liʻiliʻi wale nō o ka noiʻi a me nā hoʻolālā hoʻomohala e alakaʻi i ka hoʻolaha ʻana i nā huahana ʻAʻole hiki i nā hopena o nā hoʻokolohua lapaʻau mua ke hōʻike i nā hopena holoʻokoʻa a i ʻole nā ​​hopena o nā hoʻokolohua lapaʻau hope a nui paha, ʻaʻole hiki. hōʻoia lākou i ka ʻae kānāwai.ʻAʻole pono ʻoe e hilinaʻi nui i kēia mau ʻōlelo a i ʻole ka ʻikepili ʻepekema i hāʻawi ʻia.
Hoʻopili kēia mau ʻōlelo i nā pilikia a me ka maopopo ʻole, a hiki ke hoʻohālikelike ʻia nā hopena maoli mai nā hopena i hōʻike ʻia i loko o ia mau ʻōlelo, e komo pū ana akā ʻaʻole i kaupalena ʻia i ka loaʻa ʻana o nā hanana palekana maikaʻi ʻole a/a i ʻole nā ​​hopohopo i manaʻo ʻole ʻia e nā ʻikepili ʻē aʻe a i ʻole ka nānā ʻana;nā lilo i manaʻo ʻole ʻia a hoʻopaneʻe paha.Hiki mai nā hopohopo i manaʻo ʻole ʻia ma muli o nā ʻikepili ʻē aʻe, ka nānā ʻana a i ʻole nā ​​hopena i ka wā o nā hoʻokolohua lapaʻau;ʻAʻole hiki iā mākou ke pale a hoʻokō i kā mākou ʻikepili, nā kuleana waiwai naʻauao a me nā kuleana ʻē aʻe, a me nā kānalua e pili ana i nā koi a me nā pilikia o ka waiwai naʻauao;Pono paha nā ʻoihana hoʻoponopono i ka ʻike hou a i ʻole ka noiʻi hou ʻana, a i ʻole hiki ke ʻae a hoʻopaneʻe paha i ka ʻae ʻia o kā mākou mau moho lāʻau lapaʻau a i ʻole ka hoʻonui ʻia ʻana o ka lepili huahana;ka loaʻa ʻole o ka ʻae hoʻoponopono ma nā ʻāina ʻē aʻe;nā koi kuleana huahana;nā pilikia o ka hui pū ʻana o nā ʻaoʻao ʻekolu;a ʻO ka maʻi maʻi COVID-19 e hoʻomau nei he mau hopena pololei a ʻole i kā mākou ʻoihana, nā hopena hana a me nā kūlana kālā.ʻO ka nui akā ʻaʻole nā ​​​​mea āpau i helu ʻia ma luna nei ke kumu i ʻokoʻa ai nā hopena maoli mai kā mākou mau manaʻo i nā ʻōlelo i mua.Pono nā mea hoʻolale kālā e noʻonoʻo i kēia ʻōlelo aʻo a me nā kumu pilikia a mākou i ʻike ai i kā mākou hōʻike makahiki a i ʻole ka hapaha makahiki a me nā hōʻike ʻē aʻe a mākou e waiho ai me ka Securities and Exchange Commission.Hoʻokumu ʻia kēia mau ʻōlelo i ko mākou mau manaʻoʻiʻo a me nā manaʻo i kēia manawa a hōʻike wale i ke kūlana e like me ka lā i hoʻokuʻu ʻia ai kēia nūhou.Inā ma muli o ka ʻike hou, nā hanana e hiki mai ana a i ʻole nā ​​​​kumu ʻē aʻe, ʻaʻole mākou e hoʻokō i ke kuleana e hoʻonui i ka lehulehu i nā ʻōlelo i mua.
Mowry EM, Beheshtian A, Waubant E, etc. ʻO ka maikaʻi o ke ola ma nā sclerosis lehulehu e pili ana i ka maʻi kaumaha a me nā hōʻailona ana o ka lolo.Nūnū.2009;72(20):1760-1765.
Lanz M, Hahn HK, Hildebrandt H. Brain atrophy a me ka cognitive impairment in multiple sclerosis: he loiloi [Paʻi ʻia nā hoʻoponopono i paʻi ʻia ma J Neurol.2008 Feb;255(2):309-10].Ka Nupepa o ka Neurology.2007;254 Pākuʻi 2: II43-II48.
Foley J, Xiong K, Hoyt T, etc. Ua hoʻololi ʻia ka pae haʻahaʻa o ka serum neurofilament i nā maʻi me ka relapsing-remitting multiple sclerosis mai natalizumab hoʻokahi i kēlā me kēia 4 pule i ka hoʻokele wā lōʻihi.AAN 2020;S10.009.
Butzkueven, Kappos L, Spelman T, etc. ʻO nā poʻe maʻi i hoʻololi i ka natalizumab no ka lōʻihi manawa lōʻihi a i ʻole ka hoʻopaʻa ʻana i ka dosing maʻamau maʻamau ʻaʻohe ʻokoʻa koʻikoʻi i nā hopena hoʻihoʻi: ka hoʻohālikelike pono ʻana o ka helu propensity o nā maʻi i ka papahana nānā TYSABRI.ECTRIMS 2019;P1033.
Yamout B, Sahraian MA, Ayoubi NE, a me nā mea'ē aʻe.Mult Scler Relat Disord.2018;24: 113-116.
Zhovtis Ryerson L, Frohman TC, Foley J, a me nā mea'ē aʻe.J Neurol Neurosurgery Psychiatry.2016;87:885-889.
Bomprezzi R, PawateS.ʻO ka hoʻonui ʻia ʻana o ka natalizumab: 7 mau makahiki o ka ʻike ma nā kikowaena ʻelua.Ther Adv Neurol Disord.2014;7: 227-231.
Mai ka lā 30 o Iune, 2020, e pili ana i ka ʻikepili hui ma hope o ke kūʻai ʻana mai nā hoʻokolohua lapaʻau o ka lāʻau lapaʻau a me ka ʻike ʻana iā TECFIDERA.
Ma Iulai 31, 2020, hui pū ʻia ka ʻikepili ma hope o ke kūʻai aku e pili ana i ka lāʻau lapaʻau a me nā hoʻokolohua lapaʻau o ka hoʻolaha ʻana iā TYSABRI.
(Bloomberg)-Ua hāʻule ke kumukūʻai o SAP SE ma kahi o 21%, ʻo ka hāʻule nui loa o ka lā hoʻokahi mai ka makahiki 1999. Ma mua, ua hoʻohaʻahaʻa ka hui ʻo Walldorf i kāna wānana kālā piha makahiki a ʻōlelo ʻo ia e manaʻo nei i kahi pōʻai hou o ka loaʻa kālā.Hoʻopaʻa ʻia i ka hapa mua o 2021, ua hōʻemi ʻia ka noi.I ka hoʻāʻo ʻana iā Christian Klein, ua lilo ʻo ia i Luna Nui kūʻokoʻa i ʻApelila.E hoʻopaneʻe ka maʻi maʻi i ka loaʻa kālā o SAP, nā kūʻai holoʻokoʻa a me nā pahuhopu waiwai hana no hoʻokahi makahiki a ʻelua paha, ʻoiai e like me ka ʻōlelo a ka ʻoihana polokalamu ma kahi ʻōlelo ma ka Lāpule.Ua ʻōlelo ʻo SAP ua manaʻo ʻo ia i ka ulu ʻana a me ka loaʻa kālā ma nā makahiki ʻelua e hiki mai ana, a e hoʻoneʻe i kāna hoʻolālā hoʻolālā no 2023 a 2025. Ua ʻōlelo ʻo Klein i kahi kūkā kūkā ma ka Pōʻakahi e manaʻo ʻo ia e ʻōlelo ʻo SAP i loko o kahi ʻōlelo ʻo ka manaʻo mua "manaʻo. e wehe hou ka ʻoihana a e maʻalahi ka hoʻopaʻa ʻana o ka heluna kanaka, e alakaʻi ana i ka hoʻomaikaʻi lohi ʻana i ke kaiapuni koi i ka hapakolu a me ka ʻehā.Ua wānana ka hui i ka makahiki 2020, e pili ana i nā kumukūʻai hoʻololi paʻa, hiki i ka loaʻa kālā i hoʻololi ʻia i ka 27,2 biliona euros i 27,8 biliona euros (32,2 biliona a 32,9 biliona kālā ʻAmelika), ʻoi aku ka haʻahaʻa ma mua o ka mea i manaʻo ʻia a hoʻonui ʻia i 28,5 biliona euros mai ka alakaʻi mua. o 27.8 biliona euros.Euro.Ua ʻōlelo pū ʻo SAP ʻaʻole e pōmaikaʻi hou kāna ʻoihana Concur mai ka loaʻa kālā e pili ana i ka huakaʻi i kēia makahiki.Ua kākau ʻo OddoBHF ʻo Nicholas David i kahi hōʻike he paʻakikī ka loaʻa ʻana o nā hopena maikaʻi mai nā hopena News.ʻO nā manaʻolana o ka mākeke no nā manaʻo o ka wā waena he / makaʻu, akā ʻoi aku ka haʻahaʻa o nā manaʻo hou ma mua o nā manaʻo pessimistic.Ua ʻōlelo ʻo Qualtrics IPOSAP aia kāna mahele polokalamu Qualtrics i ka pae holomua o ka papa inoa.Ua hoʻolaha ʻo ia i Iulai ua hoʻoholo ʻo ia e kiʻi i ka hui ma ke kumukūʻai moʻolelo a hele i ka lehulehu ma US ma lalo o ʻelua makahiki.He hoʻololi i manaʻo ʻole ʻia kēia a hōʻike i kahi hoʻololi hoʻolālā ma lalo o ke alakaʻi ʻana a Klein."Ua holomua loa mākou i ka hoʻomākaukau ʻana no Qualtrics 'IPO," i ʻōlelo ʻia e ka Luna Nui kālā ʻo Luka Mucic ma ke kelepona ma ka Pōʻakahi."E hoʻokumu ʻia ka hana ikaika a Qualtrics i kēlā me kēia makahiki i ka makahiki aʻe."Manaʻo ka manaʻo hou e hoʻonui i ka loaʻa kālā mai 8 biliona euros a i 8.2 biliona euros ma 2020, haʻahaʻa ma mua o ka manaʻo mua o 8.3 biliona euros i 8.7 biliona euros.ʻO ka loaʻa kālā o ka Euro Euro i kēia makahiki ma waena o 8.1 biliona Euro a me 8.5 biliona Euro, ʻoi aku ka haʻahaʻa ma mua o ka 8.7 biliona Euro i manaʻo ʻia.Ua hoʻonui ʻo SAP i kāna pahuhopu waena e ʻoi aku ma mua o 36 biliona Euro ma ka huina kālā ma 2025 a hiki i ka 35 biliona Euro ma 2023. , Ma ka 2025, ʻoi aku ka nui o ka loaʻa kālā o ke ao ma mua o 22 billion euros a ʻoi aku ka waiwai o ka hana ma mua o 11,5 billion euros.ʻO ka loaʻa kālā o ka hapakolu o ka hapakolu non-IFRS i ke kolu o ka hapaha hāʻule i ka 12% makahiki i ka makahiki i ka 2.07 biliona euros.Hoʻohālikelike ʻia me ka 2.15 biliona euros i manaʻo ʻia e nā mea loiloi i noiʻi ʻia e Bloomberg, ua hāʻule ka loaʻa kālā i ka wā o 4% a i 6.54 biliona euros, aʻo ka wanana awelika o ka mea loiloi he 6.89 biliona euros., Luna Nui o SAP ma o PandemicU.K.Hoʻomaka ka CMA i kona ala ponoʻī a hoʻomaka i kahi hoʻokolokolo antitrust e kūʻē iā Sinch, ua hāʻawi ʻia ka māhele SAP DealSAP iā JP Morgan Stanley, a ua alakaʻi ʻo JP Morgan i ka Qualtrics IPO (nā hoʻoponopono waiwai, nā kūlana ʻē aʻe).E ʻoluʻolu e kipa i Bloomberg.com e kipa mai iā mākou a kau inoa i kēia manawa.E mālama i kahi kūlana alakaʻi ma ke ʻano he kumu hilinaʻi nui o ka nūhou ʻoihana.©2020 Bloomberg LP
Ua kūkākūkā kahi moʻohelu kālā o Kapalakiko i ke koʻikoʻi o ka hoʻokele Biden i nā waihona hoʻopukapuka kālā i kēlā me kēia kamaʻilio me nā mea kūʻai aku.
ʻO nā mea hoʻohana ʻaʻole i kau i kahi kauoha ma kekahi kahua o JD hiki ke loaʻa i nā coupons hoʻemi!Me kāu kāleka Visa, kaomi e uku ma JD.com no ka manawa mua a hauʻoli i nā uku hoʻemi!
ʻO ka Nobel laureate i ka ʻoihana waiwai, ua koi ʻo ke kaukaʻi ʻo Yale University ʻo Robert Shiller i nā mea hoʻopukapuka e makaʻala e pili ana i ka mākeke stock blockbuster i kahi kolamu hou i ka New York Times.
Ua ʻōlelo ka hui ʻo Lee Kun-hee, nāna i kūkulu ʻo Samsung Electronics i kahi kanaka nunui honua i nā smartphones, semiconductors a me nā TV, ua make i ka lā Lāpule ma hope o ka hoʻokipa ʻia ʻana no nā makahiki ʻeono me ka puʻuwai puʻuwai i ka lā Lāpule.He 78 makahiki o Lee i keia makahiki.Ua hoʻomohala ʻo ia i ka Samsung Group i ka hui nui loa ma South Korea a lilo i kanaka waiwai loa ma South Korea.Ua ʻōlelo ʻo Jeong Sun-, Luna Nui o ka hui noiʻi ʻoihana ʻo Chaebul.com: "ʻO ka piʻi ʻana o Lee i Korea a me ke ʻano o ka hoʻohui ʻana o South Korea i ka honua honua he hōʻailona ia e hoʻomanaʻo ʻia ai kona make e nā poʻe Korea he nui.
ʻEhā makahiki ma hope o ka hāʻule ʻana o ka BHS, ua hoʻololi ʻia ka ʻoihana loiloi i hoʻohewa ʻia no ka loaʻa ʻole o nā pilikia?
Wahi a CNBC hōʻike, ʻo Jack Ma, ka mea nāna i hoʻokumu iā Alibaba Group Holdings Limited (NYSE: BABA), i ʻōlelo ʻia i ka Pōʻaono e lilo nā ʻelua o nā makana lehulehu mua a Ant Group (IPOs) ma Shanghai a me Hong Kong i ka hui nui loa o ka honua.He aha ka mea: Ua ʻōlelo ʻo CNBC ʻo ke kumukūʻai IPO i ka pō Pōʻalima, akā ʻaʻole i hōʻike ʻo Jack Ma i ka helu kikoʻī, e hoʻolaha ʻia i kēia pule aʻe.Ua hoʻoholo ʻia ka mōʻaukala kanaka ma waho o New York City."Ua ʻōlelo ʻo Ma Yun ma Shanghai Bund Summit.Ua kapa ka billionaire Kina i ka pilikia he "hana mana."Ua ʻōlelo ʻo ia: “ʻAʻole mākou i ʻaʻa e noʻonoʻo e pili ana i ʻelima a ʻekolu paha makahiki i hala.“Ua kāhea ʻo Ma Yun no ka hoʻoponopono ʻana i ka panakō a no ka hoʻokumu ʻana i kahi ʻōnaehana waihona kālā hou.No ke aha he mea nui: ʻO nā makana mua o nā hui i kākoʻo ʻia e Alibaba hiki ke hoʻohua i kahi kokoke i hoʻokahi piliona kālā, e lilo ia i Saudi Aramco ʻO ka makana mua nui loa o ka honua ma mua o US $ 29.4 biliona.ʻO ka waiwai o Aramco i hoʻopuka ʻia ma Dekemaba 2019 ua lanakila ʻo Alibaba a lanakila i ka lei o ka IPO nui loa.Wahi a nā hōʻike, hiki ke hoʻopaʻa inoa ʻia ke kālā waiwai nui o Singapore GIC Private Limited i kēia mau papa inoa ʻelua.ʻOi aku ka hoʻopukapuka kālā ma mua o US $ 1 biliona.Wahi a Reuters, ua hōʻike pū ʻo Temasek o Singapore, kahi mea hoʻopukapuka Ant i kēia manawa, i ka hoihoi i ke kumukūʻai.Ka hana kumu kūʻai: Ua pani ʻia ke kumukūʻai kūʻai o Alibaba ma kahi o 1.2% ma ka Pōʻalima a i US $309.92.Ua piʻi ʻo 0.11% i ka wā kālepa ma hope o nā hola.ʻO nā makana hou aʻe mai Ben Singa * Kaomi ma aneʻi e ʻike i nā kālepa koho a Ben Singa * Ua hāʻule ʻo Quibi-ʻaʻole ikaika kēia manaʻo, ʻōlelo ʻo Benzinga.com alakaʻi (C) i 2020: "A i ʻole "Ka manawa" nalo.ʻAʻole hāʻawi ʻo Benzinga i ka ʻōlelo aʻo kālā.Ua mālama ʻia nā pono āpau.
Hāʻawi koke i ke kākoʻo ʻana i ke keʻena puʻuhonua UN, i hiki i nā mea mahuka ke loaʻa nā pahu pilikia e hoʻoponopono ai i ka wā ua a hoʻopakele iā lākou mai ka pōʻino!
He mea maʻalahi ke kūʻaiʻana i nā kumukūʻai, akā paʻakikī ke kūʻaiʻana i nā kumukūʻai kūpono me kaʻole o ka hoʻolālā manawa.No laila, he aha ke kumukūʻai maikaʻi loa e kūʻai ai a kau ʻia ma ka papa kiaʻi i kēia manawa?
Ua hāʻule nui nā wā e hiki mai ana.Hiki ke hele ka mākeke me nā alakaʻi e like me Microsoft a me Tesla.Ke kokoke mai nei nā koho balota a ua piʻi nā hihia coronavirus, ʻo ia ka pule loaʻa loa.
Ua ʻike ʻo Harry Markopolos (Harry Markopolos), he loea derivatives mua i huli i kahi mea noiʻi hoʻopunipuni kālā kūʻokoʻa, ʻike i ka papahana Bernie Madoff Ponzi $ 65 biliona, akā ua mālama ʻole ʻia e ka SEC No ʻeiwa mau makahiki.Ma ke ʻano he ʻōlelo hoʻohewa kūwaho o nā mea hoʻoponopono US, ʻike ʻo Harry i ke kahua o ka loiloi a me ka ʻoihana ʻinikua ʻo ia ka hihia hoʻopunipuni kālā nui e hōʻike ʻia.
Hāʻawi ʻo Hang Seng i ka makahiki hou i hiki ke unuhi ʻia i ka ʻauhau ma ka pūnaewele he 10 mau makahiki o ka loaʻa kālā paʻa a hōʻoia i ka 1.73%-2% o ka hoʻihoʻi ʻana i ka loaʻa kālā.He 10 mau minuke wale nō e noi ai no ka ʻinikua ma ka pūnaewele a hana koke.
ʻEkolu poʻe i kamaʻāina i kēia mea i ʻōlelo ʻia ua hoʻonohonoho ka mea hoʻohui kiʻekiʻe o ka iPhone, ʻo Foxconn ma Taiwan, i kahi hui hana e pale aku i ka ulu ʻana o ka mana o ka mea hana uila Kina ʻo Luxshare.Manaʻo ka ʻoihana ʻo Luxshare ke aupuni.hooweliweli nui.Ua ʻōlelo kekahi o nā kumu, ua hoʻokumu ʻia ka papahana e ka mea hoʻokumu ʻo Foxconn ʻo Guo Taiming a ʻo ka pahuhopu ʻo Luxshare <002475.SZ> ke keʻena nui ma Dongguan.ʻAʻole ʻike liʻiliʻi ka ʻoihana ma ka honua, akā manaʻo ʻia e lilo i hui mua e ʻākoakoa ma ka ʻāina ʻo Kina.ʻO ke keʻena nui o iPhone-a hiki i kēia manawa, ua hoʻomau ʻia ka turf e nā mea hana Taiwanese.Ua ʻōlelo ke kumu ua hoʻokumu ʻia ka hui hana i ka makahiki i hala a ke noiʻi nei i ka ʻenehana o Luxshare, nā hoʻolālā hoʻonui, ka hoʻolālā hoʻolālā a inā paha i kākoʻo ʻia ka hui (ʻo ia wale nō ka 5% o ka loaʻa kālā o Foxconn) e kekahi hui aupuni Kina.
E hoʻokuʻu ʻia ka hōʻike kālā nui a me ka ʻikepili waiwai o kēia pule ma hope o kēia pule, a ʻo ka hapa nui o nā waihona FAANG e hōʻike ʻia ma hope o ka pani ʻana i ka Pōʻalima.
E hoʻokuʻu ʻia ka hōʻike kālā ʻekolu hapahā o AMD (AMD) ma hope o ka pani ʻana i ka Pōʻalua, he manawa hoihoi ia no ka ʻoihana semiconductor.Ua hōʻike ka Wall Street Journal e hoʻolālā ana ʻo AMD (AMD) e hoʻonui i kāna ʻoihana ma o ka loaʻa ʻana (XLNX) (XLNX).I ka manawa like, ke hana ikaika nei kāna mea hoʻokūkū nui (INTC) e hoʻomau i ka hana ʻana i nā ʻenehana hana kiʻekiʻe e pono ai e hana i nā semiconductor kiʻekiʻe.
E kūʻai ma nā hale kūʻai pūnaewele nui a hoʻolilo me ka kāleka Visa e hauʻoli a hiki i ka 20% ka uku!E ʻike i nā hōʻiliʻili hou o Luisa Via Roma a me Taylor i kēia manawa!
Ua ʻōlelo ʻo CFRA ʻo Garrett Nelson i ka hālāwai ninaninau me Yahoo Finance ma ka Pōʻalima inā lanakila ʻo Joe Biden (Joe Biden) i ke koho pelekikena, ʻo Tesla (NASDAQ: TSLA) ka lanakila nui loa.He aha ka mea: Ua ʻōlelo ʻo Nielsen e lilo ʻo Tesla i "kekahi o nā hui nui" lanakila no ka mea he "kaʻa uila maʻemaʻe ka hui."Ua kuhikuhi ka mea loiloi e hāʻawi ke aupuni Biden i nā kālā nui no nā kaʻa uila.Ua kuhikuhi ʻo CFRA Analysts ua manaʻo ʻo Biden i ka "hoʻonui nui ʻana i nā ʻauhau ʻauhau kaʻa uila" a me ka "kūkulu nui o nā keʻena kaʻa kaʻa uila."Ua ʻōlelo ʻo Nielsen: "Ke noʻonoʻo nei ʻoe e hoʻonui i ka nui o nā kikowaena kaʻa uila ma kahi o 20 mau manawa.E kōkua maoli ia i ka hoʻolaha ʻana o nā kaʻa uila."He mea nui: I ka wā o ka hoʻopaʻapaʻa pelekikena hope loa ma Tennessee i ka pule i hala, ua ʻōlelo ʻo Biden e hoʻolilo kāna aupuni i 50,000 mau kaʻa kaʻa uila ma ke alaloa.Ua ʻōlelo ka poʻe moho e alakaʻi kēia mau keena hoʻoili i ka United States e loaʻa i kahi "hopena."Manaʻo ka hope pelekikena mua e hiki i kāna ʻike no nā kaʻa uila ke hoʻoponopono i ka hoʻololi ʻana i ke aniau a hana i "nā hana uku kiʻekiʻe."ʻO ka hui i alakaʻi ʻia e Elon Musk i hoʻolaha i ke kolu o ka pule i hala ʻO ka loaʻa kālā he US $ 8.77 biliona, kahi hoʻonui o 39% makahiki ma ka makahiki;Ka hana kumu kūʻai: Ua pani ʻia nā ʻāpana Tesla ma kahi o 1.2% ma ka Pōʻalima a i US $ 420.63.Inā lanakila ʻo Joe Biden i ka TSLA DateFirmActionMai ka mea hou loa i ke koho balota ʻOkakopa 2020 Ratings Morgan Stanley e mālama i nā kaupaona like (ʻOkakopa 2020) mālama ʻo Canaccord Genuity i nā kālepa i mālama ʻia ma ʻOkakopa 2020 a ʻoi aku ka maikaʻi ma mua o ka mākeke ākea.E ʻike i nā loiloi loiloi hou aku no TSLA.E ʻike i nā loiloi loiloi hou loa * ʻO ka loiloi hou a Benza o ke kālepa * Ua ʻōlelo ʻo Rives Musk e loaʻa nā lawelawe hoʻolimalima mahina i ka makahiki aʻe.Ua ʻōlelo ʻo Jim Kramer ʻo Jim Tesla he "huka pupule" ma 2020 (C) Benzinga.com, ʻo ia ka "hewa" ʻaʻole hāʻawi ʻo Benzinga i nā ʻōlelo aʻo kālā.Ua mālama ʻia nā kuleana āpau.
ʻO wai ka hoʻolālā waiwai i kū i ka hoʻāʻo o ka manawa?Hoʻokomo kālā ulu.Manaʻo ka poʻe loea o Wall Street e hōʻike ana nā kumulāʻau me nā manaʻo ulu nui i kekahi o nā kumulāʻau koʻikoʻi.ʻOi aku ka nui o kēia ulu ulu ʻana, a e loaʻa kēia mau inoa i nā hoʻihoʻi nui ma 2020 a ma waho.ʻO kēlā'ōlelo, no ka'ōlelo liʻiliʻi loa, hiki ke paʻakikī ka loaʻaʻana o nā kumukūʻai i hāʻule i kēia māhele.Manaʻo ka poʻe loiloi hoʻokahi hoʻolālā e hoʻihoʻi i hope, e nānā i ke kiʻi nui, a nānā i nā ʻoihana i ulu lōʻihi ma muli o nā hoʻokō maikaʻi loa i kēlā me kēia makahiki.Ma ka hoʻomanaʻo ʻana i kēia, ua hoʻohana mākou i ka ʻikepili ʻo TipRanks no ka ʻike ʻana i ʻekolu mau mea ulu ulu i loiloi nui ʻia e nā mea loiloi.Ua loaʻa i nā ʻāpana ʻekolu i ka ulu nui ma 2020 a mākaukau e hoʻomau i ka piʻi.ʻO Pennsylvania National Game Company (PENN) ʻO ka mea mua, nona ka Pennsylvania National Game Company, nona a mālama i nā keʻena pāʻani a me nā heihei a me nā ʻoihana pāʻani wikiō ma ʻAmelika Hui Pū ʻIa.Ua piʻi ka inoa i ka 146% makahiki a hiki i kēia lā, akā manaʻo kekahi poʻe loiloi Wall Street he nui ka wahie i loko o ka pahu.Ua hoʻolaha mua ʻo PENN i kāna mau hopena hapaha ʻekolu ma mua, ʻoi aku ia ma mua o nā mea i manaʻo ʻia.Manaʻo ka ʻoihana e hoʻonui ʻia nā palena kālā no ka hapaha ma mua o 900 kumu kumu, a ʻo ka EBITDAR i hoʻoponopono ʻia e ulu ʻia e 5% i kēlā me kēia makahiki, ʻoiai inā e hāʻule ka loaʻa kālā he 10% makahiki-ma-makahiki.Ua haʻi aku ʻo Joseph Greff, ka mea loiloi ʻelima-hōkū i nā mea kūʻai aku, ʻo "JP Morgan Chase" i ʻōlelo: "Ua hoʻomau ka hoʻihoʻi ʻana o ka ʻoihana pāʻani kūloko i Mei / Iune a hiki i ke kolu o ka hapaha, a ʻoi aku ka maikaʻi o ka loaʻa kālā ma mua o ka mea i manaʻo ʻia.I ka manawa i kāohi ʻia ai ka noi Ma hope o ka hoʻi ʻana i ka maʻamau, a mai ka hoʻomaikaʻi ʻana o ka maikaʻi o ka COVID ma mua, ʻaʻole i piʻi a piʻi ka hoʻolimalima hana.Ua manaʻo mua mākou ua lohi ka ulu ʻana. "Ma ka ʻōlelo ʻana i kēlā, ua ʻae ʻo Greif i ka hāʻawi ʻana i ke kumukūʻai kumukūʻai koʻikoʻi, ua haʻalele kekahi mau mea loiloi ʻē aʻe.Eia nō naʻe, ke manaʻoʻiʻo nei ʻo ia "ka waiwai a me ka mea hoʻoikaika no ka wā e hiki mai ana".Ua ʻōlelo ka poʻe loiloi: “… Aia ke ʻano o ke kaua i ka manaʻo o nā mea hoʻopukapuka.Ke manaʻoʻiʻo nei mākou he olakino kēia no nā kumukūʻai a aneane pono e hoʻomau i ka piʻi ʻana o nā waihona;Ke manaʻoʻiʻo nei mākou ʻaʻole i hoʻoweliweli ʻia nā mea hoʻopukapuka kālā maʻamau.Ke manaʻoʻiʻo nei mākou he kānalua nā mea hoʻopukapuka e pili ana i ka hiki o PENN ke hoʻokūkū me DraftKings, Fanduel, Caesars Entertainment, MGM/GVC, a pēlā aku. ʻO ka hōʻiliʻili kālā i hōʻiliʻili ʻia he $950 miliona, ua hōʻemi ʻia ka pilikia o kēia hoʻokūkū i loko o kahi kikoʻī.ʻO ka mea nui loa, ua hoʻokumu ʻo PENN i ka Barstool Sports betting app ma Pennsylvania.Ua kapa ʻo Greff i kēia hoʻokuʻu mua ʻana "e hoʻoikaika i nā ʻōlelo o ka nui a me nā lilo kūʻai aku," a ua hōʻike ʻo ia i "ka hiki ke loaʻa kahi ala kūʻokoʻa e loaʻa ai ka ʻāpana."Eia hou, ke piʻi nei ka manawa o Barstool Sportsbook.ʻO ka mea nui aʻe, manaʻo ʻo Greff ʻo ka pili ʻana i nā haʻuki a me ka iGaming kaiapuni e like me ka piʻi ʻana o nā mākeke kūloko i nā makahiki 1990, i ka wā i huli ai nā mokuʻāina me nā hemahema kālā i nā kumu kālā hou, e like me nā pāʻani kahawai e kōkua i ka uhi ʻana i kā lākou kālā.hemahema.Ma kēia mea, ua ʻōlelo ka mea loiloi: "Ke manaʻoʻiʻo nei mākou ua aneane like nā manaʻo o kēlā me kēia mokuʻāina no USSB a me iGaming, a ʻo PENN kekahi o nā mea lanakila.Makemake mākou i ke ʻano pāʻani pāʻani / pāʻani pāʻani / iGaming ma US a ʻike i kahi lumi no ka ulu ʻana..”ʻAe, ʻaʻole ia he mea kupanaha i noho ʻo Grave me nā Bulls.Ma waho aʻe o ka hāʻawi ʻana i ka helu "overweight", ua hoʻonohonoho pū ʻo ia i kahi kumu kūʻai o $83 no ke kumukūʻai.Inā hoʻokō ʻia kēia pahuhopu i loko o nā mahina he ʻumikūmālua e hiki mai ana, hiki i nā mea hoʻopukapuka kālā ke loaʻa he 32% hoʻihoʻi.(No ka nānā ʻana i ka moʻolelo mele a Greif, kaomi ma aneʻi.) He aha ka ʻōlelo a ke koena o Wall Street?ʻEiwa kūʻai, ʻekolu mau paʻa a hoʻokahi kūʻai i hoʻopuka ʻia i nā mahina ʻekolu i hala.ʻO ka hopena, ua loaʻa iā PENN kahi helu ʻae "medium buy".Ma muli o ke kumu kūʻai maʻamau o $ 76.77, hiki ke piʻi ke kumukūʻai ma 22% i ka makahiki aʻe.(E nānā i ka nānā ʻana o ka waihona kālā ʻo Penn National Gaming ma TipRanks.) Ua hoʻomaka ʻo Redfin (RDFN) Redfin me kahi wahi huli ma ka palapala ʻāina a hoʻonui i kāna ʻano huahana e hana i nā pāʻani ʻohana, nā hoʻomaka a me nā kaʻina hoʻokipa ʻoi aku ka wikiwiki a me ka maʻalahi.Ma Wall Street, manaʻo kekahi poʻe ʻaʻole wale ka inoa e pili ana i ka piʻi ʻana o ka noi COVID, a ʻo kāna loaʻa 113% makahiki a hiki i kēia lā ka hoʻomaka.ʻOiai ua hoʻopau ʻo RDFN i ka wānana ikaika o ka hapaha kolu, ua hoʻohilahila ʻia nā mea hoʻopukapuka i ka hopena.Ua kuhikuhi ʻo Jake Fuller o BTIG e hāʻule paha ke kumukūʻai no ka mea "he kiʻekiʻe nā manaʻolana a ʻo ka piʻi haʻahaʻa o ka nui o ka loaʻa kālā ma kahi o 2%" a "ʻoi aku ka nui o nā mea hoʻopukapuka manawaleʻa e uku i kahi mele i alakaʻi ʻia, ʻoiai ʻo RDFN ke waiho nei ma hope o kēia manaʻolana."Manaʻo ʻo Fuller ʻaʻole ʻo RDFN ka manaʻo o ka nui o ka poʻe, e hōʻike ana ʻaʻole i ʻike paha nā mea hoʻopukapuka i ka hōʻike ʻana i ka loaʻa kālā.Eia naʻe, manaʻo ʻo ia e hala paha ʻo Wall Street i ka ʻāpana nui o ka puzzle.Ua ʻōlelo ka mea loiloi ʻelima-hōkū: "ʻO ka mea e poina ʻia ma ʻaneʻi, ua hoʻonui ʻo RDFN i ka helu komisina me ka ʻole o ka hopena koʻikoʻi i ka helu hoʻololi, e hoʻomaikaʻi nui i ka ʻike no ka loaʻa kālā nui o RDFN."I kēia hopena, e manaʻo ʻia e hoʻonui ʻia ka waiwai nui o 2021 e 47%.Ke nānā pono nei i ka ʻike kikoʻī no ka hapaha, ua ʻike ʻo RDFN i ka koi ikaika a me ka loaʻa kālā o nā lawelawe waiwai i ulu 36% makahiki-ma-makahiki.Ua hoʻonui pū ʻia ka nui o ka pūnaewele a me ka nui o nā kālepa i kēlā me kēia mahina.Eia nō naʻe, pono e hoʻomaopopo ʻia ʻo ka upside e alakaʻi ʻia e ka loaʻa kālā o kēlā me kēia kālepa.Ua ʻōlelo ʻo Fuller: "He mea nui kēia no ka mea e hōʻike ana e hāʻawi hope ka helu komisina i manaʻo ʻia.""E like me kā mākou helu helu, loaʻa nā lawelawe waiwai mai 1.68% o GTV i ke kolu o ka hapaha o 2019 a me ka lua o ka hapaha o 2020 1.78% i hoʻonui ʻia i ka 1.85% i ke kolu o ka hapaha o 2020. kaʻa nui ma kēia wahi.ʻOiai paʻakikī ka loiloi i ka hoʻomau ʻana o ka noi, ʻo ka piʻi ʻana o ke kumukūʻai a ʻoi aku ka maikaʻi o ka loaʻa kālā ʻoi aku ka paʻa ʻana "i ʻōlelo ai ʻo Fowler.E like me kona manaʻo maikaʻi, ua kākoʻo ʻo Fuller i nā bipi, e ʻōlelo hou ana i ka helu kūʻai a me ke kumu kūʻai kumu kūʻai o $65.Hōʻike kēia pahuhopu i kona hilinaʻi i ka hiki o RDFN ke hoʻonui i 45% i ka makahiki aʻe.(No ka ʻike ʻana i ka moʻolelo mele a Fuller, kaomi ma aneʻi.) I ka neʻe ʻana i nā wahi ʻē aʻe o Wall Street, ua ʻoi aku ka māhele ʻana o nā manaʻo.I nā mahina ʻekolu i hala iho nei, ua hoʻokaʻawale ʻia nā kūʻai 6, 5 mau paʻa a me 1 kūʻai.Wahi a Wall Street, ʻo RDFN kahi kūʻai waena.ʻO ke kumu kūʻai maʻamau o $50 ʻo ia ka 11% upside.(E nānā i ka nānā ʻana o ka waihona Redfin ma TipRanks) ʻO Vertiv Holdings (VRT) Ma ke ʻano he mea nui o ka honua, nā lako polokalamu a me nā lawelawe lawelawe, ua kōkua ʻo Vertiv Holdings i ka hoʻolaha ʻana i ka mākeke pili o nā ʻōnaehana kikohoʻe, kahi nui o nā mea pono e pono ai. e hoʻouna ʻia, e kālailai ʻia, e hana a mālama ʻia.Ua ʻōlelo ʻo Wall Street ua piʻi ʻo ia i ka 71% a hiki i kēia makahiki, a ʻoi aku ka nui o nā lanakila.ʻOiai inā piʻi nui ke kumukūʻai o ke kumukūʻai, manaʻoʻiʻo nō ka mea loiloi ʻo Wolfe Research ʻo Nigel Coe he maikaʻi ke kūlana pilikia / uku.Ua wehewehe ʻo ia: "Ke manaʻoʻiʻo nei mākou he ʻano laha ʻo Vertiv e hiki ke huki i ka lehulehu o nā mea hoʻopukapuka: kahi ʻoihana ulu nui e hiki ke hāʻawi i ka ulu waiwai maikaʻi ma ke kumukūʻai a aia ma lalo o ke kuleana o kahi hui hoʻokō kiʻekiʻe."I ka hiki ʻana mai i ka VRT Ma ke ala e ulu ai, ʻo kāna mau mākeke hopena nui nā kikowaena data a me ke kelepona.ʻO kēia mau wahi nā wahi i manaʻo ai ʻo Coe e hoʻokō i ka ulu ʻana ma 2020 a me 2021, a me nā pōʻino lōʻihi lōʻihi i lawe ʻia e ka hoʻonui mau ʻana i ka ikaika o ka ʻikepili a me nā hoʻonui 5G.Eia kekahi, i alakaʻi ʻia e ka hoʻoikaika ʻana e hoʻomau i nā kumukūʻai paʻa ma o ka hoʻonui ʻana i ka hana a me ka hōʻemi ʻana i ka paʻakikī o ka hoʻonohonoho ʻana, ua wehewehe ka hoʻokele i kahi ala e hoʻonui ai i ka loaʻa kālā i 500 kumu kumu."He palapala kēia i hoʻopuka maikaʻi ʻia e ka luna hoʻokele ʻo David Cote i kona noho ʻana ma Honeywell, kahi e hōʻoiaʻiʻo ai iā mākou e hiki ke kau ʻia nā palapala like ma Vertiv," wahi a Cohen.He mea pono ke hoʻomaopopo ʻia ua haʻalele ʻo VRT i ka lua o ka hapaha o 2020, me ka ʻaiʻē net ma kahi o US $ 2.1 biliona a me ka hōʻaiʻē net / EBITDA a hiki i 4.2 mau manawa.ʻOiai ma ka hopena kiʻekiʻe o kēia pae, manaʻoʻiʻo ʻo Coe e hiki ke hoʻokuʻu koke ka waihona kaulike.I kēia hopena, manaʻo ʻo ia ma ka makahiki 2023 ʻelua ka nui o ka hōʻaiʻē net / EBITDA, a laila e hiki ke koena kālā i 1 biliona kālā US."ʻAʻole mākou i manaʻo i kēia manawa he moʻolelo hoʻopukapuka kālā ʻo Vertiv, akā hiki i kēia ke puka i loko o ka manawa o 2022/23-hiki iā mākou ke ʻike i nā hana kūʻai e hoʻomaikaʻi i kona hiki i ke kahua hoʻohele mana a me ka papa DCIM.ʻO nā koho ʻē aʻe e pili ana i ka hoʻokaʻawale ʻana i nā palapala hōʻoia kālā (e hōʻike ʻia kēia i kēia manawa i kā mākou helu helu ʻana i hoʻoheheʻe ʻia) a me ke ʻano o ka puʻunaue ʻana i nā ʻāpana, kahi e hoʻonui ai i ka hiki ke loaʻa ka ʻoihana.ʻAʻole hiki iā mākou ke haʻalele i ka ʻoiaʻiʻo o ka nui o nā lako uila ʻoi aku ka nui o nā hui hoʻolālā i hoʻokumu ʻia e nā mea kūʻai aku ma ka mākeke, ʻaʻole kēia poʻe i komo nui i ka kikowaena data.ʻO nā mea a pau a VRT i hana ai ua hoʻohuli iā Coe e haʻi hou i kāna helu outperform.ʻOiai ke kāhea ʻana i nā koho, ua hoʻonohonoho ʻo ia i kahi kumu kūʻai o $ 23, e hōʻike ana i kahi 22% upside hiki.(No ka nānā ʻana i ka moʻolelo mele a Coe, kaomi ma aneʻi) Ua ʻae anei nā mea loiloi ʻē aʻe?ʻo lākou.I nā mahina ʻekolu i hala iho nei, ua paʻi ʻia nā helu "kūʻai" pololei 4 wale nō.No laila, maopopo ka ʻōlelo: VRT kahi kūʻai ikaika.Hāʻawi ʻia ʻo ka awelika kumu kūʻai he $20.75, hiki ke piʻi ke kumu kūʻai ma 10% i ka makahiki aʻe.(E ʻike i ka nānā ʻana o nā kumukūʻai ʻo Vertiv Holdings ma TipRanks) Hōʻole: ʻO nā manaʻo i hōʻike ʻia ma kēia ʻatikala ʻo ia wale nō nā manaʻo o ka mea loiloi nui.No ke kuhikuhi wale nō ka ʻike.Ma mua o ka hana ʻana i kekahi hoʻopukapuka kālā, he mea nui ia e hana i kāu loiloi ponoʻī.
ʻO Microsoft, Apple, Alphabet, Facebook, Amazon, AMD, Caterpillar, Comcast, GE, Ford, Pfixer, Visa, UPS, Exxon Mobil, Twitter a me nā hui ʻē aʻe i hōʻike i kā lākou hopena hapahā.
ʻO kahi kahua kaʻana like hou no Hong Kong SMEs-"HSBC Airport" e hoʻopili iā ʻoe i nā ʻike ʻoihana like ʻole a me nā hanana
I ka pule e pau ana i ka la 22 o Okatoba, ua emi iho ka huina o ka moraki i na haahaa.Manaʻo ʻia e hoʻomau ka hopena o COVID-19 a me ʻAmelika i kēia pule.
E ʻike ʻo Trifecta Stocks i nā kumukūʻai bearish i kēlā me kēia Pōʻakolu, a aia paha kekahi mau manawa hoʻolimalima hoihoi i ka wā pōkole.Me ka hoʻohana ʻana i ka loiloi ʻenehana o kēia mau papa kiʻi, a ma kahi kūpono, e pili ana i nā hana a me nā loiloi hou a TheStreet's Quant Ratings, ua hoʻopau mākou i nā inoa ʻelima.ʻOiai ʻaʻole mākou e noʻonoʻo i ka loiloi kumu, manaʻolana mākou e hāʻawi kēia ʻatikala i nā mea hoʻopukapuka hoihoi i nā waihona me kahi hoʻomaka maikaʻi no ka haʻawina home hou ma ka inoa.
Ma hope o nā makahiki o ka hana ʻana i ke kinoea shale ʻAmelika, ke koho nei ʻo Chevron i kāna kinoea kūlohelohe i ka wā e hiki mai ana ma ka ʻāina paʻakikī o ka Hikina Waena, a ua makaʻala ka poʻe loea ikehu.Ua kākoʻo ʻia ka manaʻo hoʻoholo o ka hui ʻo Michael Wirth e ka pili e komo ana ka Middle East i kahi au o ka hoʻolauleʻa ʻana, kahi e lilo ai ia i koho kūpono no ka lawe ʻana i ke kinoea maoli, no ka mea, ua manaʻo ʻia e emi ke kumukūʻai ma mua o nā wahie maʻemaʻe.E ʻoi aku ka makemake ma mua o ka ʻaila.ʻO ka hoʻolālā hou ʻo ia ka hoʻolaha ʻana o ka hui i nā kālepa kinoea kūlohelohe hou ma ʻAigupita, Israel, a me Qatar, ʻoiai e hōʻemi ana i ka hoʻolilo ʻana i ka ʻimi shale ma United States.